Mata Ignacio F, Kachergus Jennifer M, Taylor Julie P, Lincoln Sarah, Aasly Jan, Lynch Timothy, Hulihan Mary M, Cobb Stephanie A, Wu Ruey-Meei, Lu Chin-Song, Lahoz Carlos, Wszolek Zbigniew K, Farrer Matthew J
Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Neurogenetics. 2005 Dec;6(4):171-7. doi: 10.1007/s10048-005-0005-1. Epub 2005 Sep 17.
Leucine-rich repeat kinase 2 (LRRK2) mutations have been implicated in autosomal dominant parkinsonism, consistent with typical levodopa-responsive Parkinson's disease. The gene maps to chromosome 12q12 and encodes a large, multifunctional protein. To identify novel LRRK2 mutations, we have sequenced 100 affected probands with family history of parkinsonism. Semiquantitative analysis was also performed in all probands to identify LRRK2 genomic multiplication or deletion. In these kindreds, referred from movement disorder clinics in many parts of Europe, Asia, and North America, parkinsonism segregates as an autosomal dominant trait. All 51 exons of the LRRK2 gene were analyzed and the frequency of all novel sequence variants was assessed within controls. The segregation of mutations with disease has been examined in larger, multiplex families. Our study identified 26 coding variants, including 15 nonsynonymous amino acid substitutions of which three affect the same codon (R1441C, R1441G, and R1441H). Seven of these coding changes seem to be pathogenic, as they segregate with disease and were not identified within controls. No multiplications or deletions were identified.
富含亮氨酸重复激酶2(LRRK2)突变与常染色体显性帕金森综合征有关,这与典型的左旋多巴反应性帕金森病相符。该基因定位于12号染色体q12区域,编码一种大型多功能蛋白。为了鉴定新的LRRK2突变,我们对100名有帕金森综合征家族史的患者进行了测序。还对所有患者进行了半定量分析,以鉴定LRRK2基因组的倍增或缺失。在这些来自欧洲、亚洲和北美许多地区运动障碍诊所转诊的家族中,帕金森综合征作为常染色体显性性状进行分离。对LRRK2基因的所有51个外显子进行了分析,并在对照中评估了所有新序列变异的频率。在更大的多个成员的家族中检查了突变与疾病的分离情况。我们的研究鉴定出26个编码变异,包括15个非同义氨基酸替换,其中3个影响相同密码子(R1441C、R1441G和R1441H)。这些编码变化中有7个似乎具有致病性,因为它们与疾病分离且在对照中未被鉴定出。未发现倍增或缺失情况。